Hijery ny anatiny

Analyse coût-efficacité des alternatives à la transfusion sanguine

Oncologie

Should intravenous iron be the standard of care in oncology? (manokatra rohy)

Auerbach M.

Loharanon-kevitra‎: J Clin Oncol 2008;26(10):1579-81.

Rakitra‎: PubMed 18375888

DOI‎: 10.1200/JCO.2007.15.4609

https://www.ncbi.nlm.nih.gov/pubmed/18375888 (manokatra rohy)

The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model. (manokatra rohy)

Borg S, Glenngård AH, Osterborg A, Persson U.

Loharanon-kevitra‎: Acta Oncol 2008;47(6):1009-17.

Rakitra‎: PubMed 18770060

DOI‎: 10.1080/02841860701744498

https://www.ncbi.nlm.nih.gov/pubmed/18770060 (manokatra rohy)

Cost of outpatient blood transfusion in cancer patients. (manokatra rohy)

Crémieux PY, Barrett B, Anderson K, Slavin MB.

Loharanon-kevitra‎: J Clin Oncol 2000;18(14):2755-61.

Rakitra‎: PubMed 10894876

DOI‎: 10.1200/JCO.2000.18.14.2755

https://www.ncbi.nlm.nih.gov/pubmed/10894876 (manokatra rohy)

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (manokatra rohy)

Mehra T, Seifert B, Bravo-Reiter S, Wanner G, Dutkowski P, Holubec T, Moos RM, Volbracht J, Manz MG, Spahn DR

Loharanon-kevitra‎: Transfusion 2015;55(12):2807-15.

Rakitra‎: PubMed 26264557

DOI‎: 10.1111/trf.13260

https://www.ncbi.nlm.nih.gov/pubmed/26264557 (manokatra rohy)